Recall rebound boosts J&J quarterly results

Share this article:

Johnson & Johnson ended the first quarter with $17.5 billion in sales, an 8.5% increase over the same period last year.

US sales were $8 billion, up just over 11% compared to the same period last year, and international sales were $9.5 billion, up just over 6%. Consumer products – which includes baby care, oral care, and OTC medications, among other categories – saw sales rise 2% over the same period last year, to $3.7 billion, up from $3.6 billion. Part of this growth comes from getting products back on shelves after a series of recalls.

Pharmaceutical sales were up around 15% in the US and 6% internationally. Notable growth spots included biologic Stelara, with sales rising 57% overall, compared to the same period last year, and 75% in the US, to $226 million, and to $120 million internationally. Sales of schizophrenia medication Invega rose 64% in the US, to $164 million for the quarter, and 98% internationally, to $120 million. Sales of prostate cancer drug Zytiga sales rose 72% overall, to $344 million, with  $161 million in US sales and $183 million internationally.
Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...